DISCOVERY: Evaluating a Decision Support Tool for Blood Cancers
This study is testing a new tool called PRIME (Preference Reporting to Improve Management and Experience) for adults with blood cancers like lymphoma, multiple myeloma, or leukemia. PRIME is designed to help you and your doctor make treatment decisions by understanding your most important priorities. Researchers want to see if using PRIME helps ensure your initial treatment choices align better with your personal values, compared to standard care. This study is open to adults aged 60 and older. Success will be measured by how well the tool improves shared decision-making between patients and doctors, as assessed by 'COLLABORATE scores' over up to 24 months.
- Study design
- This is an interventional study planning to enroll 500 participants. It compares the PRIME decision support tool to usual care.
- What's involved
- You would need to provide written or verbal informed consent and be willing to follow study procedures.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your participation will be assessed for up to 24 months to measure the study's primary outcome.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Daniel R Richardson, MD, MA, MSc · PRINCIPAL_INVESTIGATOR · UNC Lineberger Comprehensive Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Difference in COLLABORATE scores between armsUp to 24 months
The effectiveness of PRIME to improve the value-concordance of treatment decisions in older subjects presenting to hematologic malignancy clinics will be determined by differences in CollaboRATE scores (Percentage in each arm that report perfect scores 15/15) at the post-treatment decision assessment between control and intervention groups. COLLABORATE scores is a Likert scale questionnaire that includes 3 questions rated from 1 to 5. Higher scores represent better patient engagement.